🔗 Share this article

Given that the United States undertakes sweeping revisions to its vaccination schedules, a particular individual has surfaced unexpectedly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 vaccinations during the global health crisis and has concentrated on potential deaths following COVID-19 vaccination in her recent tenure at the Food and Drug Administration.

Proposed Changes to Pediatric Vaccine Schedule

Agency leaders planned to announce major changes to the pediatric immunization program recently, synchronizing the US with the Danish national calendar, sources say – a substantial departure that would put the US out of alignment with many the global community with insufficient data for public health gain. The planned update has been postponed until the new year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to present at the meeting. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this calendar year.

Consolidating Power at the FDA

Høeg's temporary position may indicate a strengthened alliance between the drug and biologics centers as Høeg and Prasad solidify control at the agency – and it points to a greater focus upon dismantling already-approved immunizations at the FDA.

The new acting director has frequently advocated for ending specific pediatric immunization guidelines in the US so as to align more similar to the Danish model, a country with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

To date comments, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, director of the FDA’s vaccine center – instead of pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has no apparent experience in drug development, regulation or leadership, which has been typical for former heads of the CBER. She has served at the FDA as a top consultant to the agency head and CBER since spring.

“It seems she lacks to have the requisite experience” for running the CDER, remarked a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in leading a large organization. She lacks background in pharmaceutical oversight.”

Past heads of the center would “be deeply familiar with laws and regulations and the science of drug development”, said Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that previous people who headed CBER have had.”

The drug center has an immense range of responsibilities at the FDA, she stated.

“Many people just focuses on the new drug program, but the off-patent medication office clears a multitude of off-brand pharmaceuticals. There is also a biosimilars program, OTC medication office and so forth, and every single one need to be looked after,” Dr. Woodcock noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership component to the role, which oversees in excess of 5,000 personnel. “It is a massive management job, if you execute it properly,” the former official said.

Response and Contentious Initiatives

When asked about questions about Høeg’s fitness for the role and whether this selection represents more teamwork among regulatory chiefs on immunizations, a press secretary said that the “concerns are based on incorrect presumptions”.

“Her resume matches the responsibilities of her position,” the official said, citing the time Høeg spent counseling the agency head on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s recently launched fast-track approval initiative, a controversial one-day drug-approval program that apparently worried her preceding directors. “By what process are these drugs being selected for this fast-track system? Who is making the decisions?” Dr. Howard said. “There is a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the Food and Drug Administration looks to be trending towards laxer rules of most medications, with the exception of shots.”

Documented Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if concerning, past, Howard have noted. She released a analysis using non-validated crowd-sourced reports to assess the rate of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida top health official Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccines are riskier than they are.

Among her “wish list” for the new federal leadership encompassed changing rules for recently developed shots and discontinuing “optional” vaccines, she stated after the election on a audio program. At the agency, Høeg has according to sources floated the idea of barring young men from getting COVID-19 vaccines.

“She is an complete ideologue who starts off with her beliefs and works backwards to retrofit the data in a very misleading, dishonest way,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined other skeptics, {like|